<?xml version="1.0" encoding="UTF-8"?>
<p id="Par10">Projects such as the “Roll Back Malaria Partnership” (RBM) must invest approximately 93 billion euros until 2030 (
 <ext-link ext-link-type="uri" xlink:href="http://www.rollbackmalaria.org" xmlns:xlink="http://www.w3.org/1999/xlink">www.rollbackmalaria.org</ext-link>) for the treatment and total eradication of malaria. However, the success of such initiatives can be compromised once again by problems caused by the resistance of 
 <italic>Plasmodium</italic> lineages. For this reason, research for the development of new antimalarial drugs must be constant. Recently, metal-based drugs have been actively explored for the treatment of a variety of parasites, with an important effect in the treatment of malaria. The following paragraphs aim to present the state-of-the-art of such strategy.
</p>
